Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Warrant (NQ:NXLIW)

0.0411 UNCHANGED
Streaming Delayed Price Updated: 10:06 AM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0411
Bid (Size) 0.0326 (15)
Ask (Size) 0.0380 (12)
Prev. Close 0.0411
Today's Range 0.0411 - 0.0411
52wk Range 0.0291 - 0.7800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
From Nexalin Technology, Inc.
Via GlobeNewswire

Performance

YTD
-90.2%
-90.2%
1 Month
-51.2%
-51.2%
3 Month
-77.0%
-77.0%
6 Month
-83.3%
-83.3%
1 Year
-77.2%
-77.2%

More News

Read More
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
From Nexalin Technology, Inc.
Via GlobeNewswire
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology CEO Provides Letter to Shareholders
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
From Nexalin Technology, Inc.
Via GlobeNewswire
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients
Via Benzinga

Frequently Asked Questions

Is Nexalin Technology, Inc. - Warrant publicly traded?
Yes, Nexalin Technology, Inc. - Warrant is publicly traded.
What exchange does Nexalin Technology, Inc. - Warrant trade on?
Nexalin Technology, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Nexalin Technology, Inc. - Warrant?
The ticker symbol for Nexalin Technology, Inc. - Warrant is NXLIW on the Nasdaq Stock Market
What is the current price of Nexalin Technology, Inc. - Warrant?
The current price of Nexalin Technology, Inc. - Warrant is 0.0411
When was Nexalin Technology, Inc. - Warrant last traded?
The last trade of Nexalin Technology, Inc. - Warrant was at 08/04/25 10:06 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.